Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Sarah Cappuyns
Observed names:
Cappuyns, Sarah,
S. Cappuyns
Institutions:
Universitair Ziekenhuis Leuven,
Hammersmith Hospital,
Imperial College London,
KU Leuven
Observed institutions:
Universitair Ziekenhuis Leuven,
Hammersmith Hospital,
VIB-KU Leuven Center for Cancer Biology,
Tisch Cancer Institute,
Imperial College London,
Icahn School of Medicine at Mount Sinai,
KU Leuven
show all 7
ORCID:
0000-0002-4521-2504
Observed ORCID:
0000-0002-4521-2504
OpenAlex ID:
A5018296557
Works
64
Awards
2
Critical Appraisal of Guideline Recommendations on Systemic Therapies for Advanced Hepatocellular Carcinoma: A Review
2023
·
Sarah Cappuyns
, Virginia Corbett
, et al.
·
JAMA Oncology
·
186
PDF
DNA methylation-driven EMT is a common mechanism of resistance to various therapeutic agents in cancer
2020
·
Eva Galle
, Bernard Thienpont
, et al.
·
Clinical Epigenetics
·
113
PDF
Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma
2024
·
Sarah Cappuyns
, Marta Piqué-Gili
, et al.
·
Journal of Hepatology
·
106
PD-1- CD45RA+ effector-memory CD8 T cells and CXCL10+ macrophages are associated with response to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma
2023
·
Sarah Cappuyns
, Gino Philips
, et al.
·
Nature Communications
·
106
PDF
Applications of single-cell multi-omics in liver cancer
2024
·
Frederik Peeters
, Sarah Cappuyns
, et al.
·
JHEP Reports
·
31
Unraveling the Synergy between Atezolizumab and Bevacizumab for the Treatment of Hepatocellular Carcinoma
2023
·
Cedric Brackenier
, Lisa Kinget
, et al.
·
Cancers
·
30
PDF
Impact of underlying liver disease on unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors
2024
·
Y. Linda Wu
, Sarah Cappuyns
, et al.
·
BJC Reports
·
22
PDF
NOTCH1 Drives Sexually Dimorphic Immune Responses in Hepatocellular Carcinoma
2024
·
Katherine E. Lindblad
, Romain Donne
, et al.
·
Cancer Discovery
·
19
Decoding tumor heterogeneity: A spatially informed pan-cancer analysis of the tumor microenvironment
2025
·
Francesca Lodi
, Sam Vanmassenhove
, et al.
·
Cell Reports Medicine
·
13
Oncogenic role of PMEPA1 and its association with immune exhaustion and TGF-β activation in HCC
2024
·
Marta Piqué-Gili
, Carmen Andreu-Oller
, et al.
·
JHEP Reports
·
9
PDF
Combination Therapies for Advanced Hepatocellular Carcinoma: Biomarkers and Unmet Needs
2022
·
Sarah Cappuyns
, Josep M. Llovet
·
Clinical Cancer Research
·
8
PDF
A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab plus bevacizumab in hepatocellular carcinoma
2026
·
Pasquale Lombardi
, Erik Ramon-Gil
, et al.
·
Journal of Hepatology
·
7
Clinical and Molecular Variables Associated With Early Progression to Checkpoint Inhibitors in MSI-High Metastatic Colorectal Cancer: A Retrospective Cohort Study
2024
·
L. Hulst
, S. Cappuyns
, et al.
·
Clinical Colorectal Cancer
·
5
Claudin-18.2 expression in gastro-oesophageal adenocarcinoma in a Western population: Overlap with other biomarkers and prognostic value.
2025
·
Filip Van Herpe
, Frederik Deman
, et al.
·
Journal of Clinical Oncology
·
4
TOP-507-YI Single-cell RNA sequencing-derived gene signatures reveal distinct response mechanisms to atezolizumab + bevacizumab in advanced hepatocellular carcinoma
2024
·
Sarah Cappuyns
, Marta Piqué-Gili
, et al.
·
Journal of Hepatology
·
3
TREM2 macrophages are associated with enhanced response to PD-1 blockade in human hepatocellular carcinoma
2025
·
Pauline Hamon
, Matthew D. Park
, et al.
·
bioRxiv (Cold Spring Harbor Laboratory)
·
2
Case report: Two sisters with light-chain cardiac amyloidosis, a mere coincidence?
2022
·
Sarah Cappuyns
, Matthias Verbesselt
, et al.
·
European Heart Journal - Case Reports
·
2
PDF
Systemic treatment paradigms for unresectable and advanced hepatocellular carcinoma in Europe
2026
·
David J. Pinato
, Eleonora Alimenti
, et al.
·
The Lancet Regional Health - Europe
·
1
Data from NOTCH1 Drives Sexually Dimorphic Immune Responses in Hepatocellular Carcinoma
2025
·
Katherine E. Lindblad
, Romain Donne
, et al.
·
1
Abstract PR03: Pretreatment immune cell composition and checkpoint ligand expression define the response to immunotherapy in advanced HCC: a study using single-cell sequencing
2022
·
Sarah Cappuyns
, Gino Philips
, et al.
·
Clinical Cancer Research
·
1
Pre-treatment cross-talk between the tumoural and peripheral immune system predicts response to checkpoint inhibition in advanced HCC: a single-cell study
2022
·
Sarah Cappuyns
, Gino Philips
, et al.
·
Journal of Hepatology
·
1
PDF
44P Cell-resolution explainable Atezolizumab+Bevacizumab Response Signature Prediction (ABRS-P) in hepatocellular carcinoma (HCC) using cell graphs
2026
·
A. Torkpour
, P. Lombardi
, et al.
·
ESMO Real World Data and Digital Oncology
PDF
244P Primary refractoriness to durvalumab plus tremelimumab in hepatocellular carcinoma
2026
·
E. Di Giacomo
, P. Lombardi
, et al.
·
Annals of Oncology
PDF
208P Neoadjuvant immunotherapy in hepatocellular carcinoma: Patterns of recurrence treatment sequencing and long-term survival outcomes from the NeoHCC cohort
2026
·
S. Cappuyns
, A. D'Alessio
, et al.
·
Annals of Oncology
PDF
Supplementary Figure S4 from NOTCH1 Drives Sexually Dimorphic Immune Responses in Hepatocellular Carcinoma
2026
·
Katherine E. Lindblad
, Romain Donne
, et al.
Show more works
View as search
Works count:
64
Citation count:
669
H-index:
9
I10-index:
9
Year
Topic
Type